GlaxoSmithKline boss Emma Walmsley said she was “extremely confident” that it would complete the giant spin-off of its consumer healthcare unit in July, despite the market volatility caused by Russia’s invasion of Ukraine.
The FTSE 100 company is demerging the unit, named Haleon last week, in what is expected to be the largest London listing for a decade and the biggest demerger in 20 years. GSK on Monday pledged to investors that the new company, which will run brands such as Sensodyne toothpaste, Panadol painkillers and Centrum vitamin supplements, would offer strong growth opportunities.
